Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Volumn 26, Issue 8, 2008, Pages 1346-1354

  El Maraghi, Robert H ^a   Eisenhauer, Elizabeth A ^a  

^a Royal Victoria Hospital Barrie   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

HUMAN; METHODOLOGY; NEOPLASM; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 41649118967     PISSN: None     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.5913     Document Type: Review

References (83)